Clinical Trials Directory

Trials / Completed

CompletedNCT04693039

Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets in Patients With Parkinson's Disease in the Early and Middle Stages

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd · Industry
Sex
All
Age
30 Years
Healthy volunteers
Not accepted

Summary

1. To evaluate the safety and tolerability of Phenlarmide tablets in patients with Parkinson's disease in the early and middle stages. 2. To evaluate the pharmacokinetics of Phenlarmide tablets in patients with Parkinson's disease. 3. To explore the efficacy of Phenlarmide tablets in the treatment of early and mid-term Parkinson's disease.

Detailed description

1. Objective to evaluate the tolerance and safety of multiple administration of fenloramide tablets in patients with early and mid-term Parkinson's disease: To evaluate the adverse events of DLT and MTD, adverse reactions, clinical laboratory tests (blood routine, blood biochemistry, coagulation function, urine routine, stool routine), vital signs, 12 lead ECG and physical examination of fenloramide tablets in patients with early and mid-term Parkinson's disease . 2. Objective to evaluate the pharmacokinetics of fenloramide tablets in patients with Parkinson's disease in early and middle stages. The main PK parameters included Tmax, SS, Cmax, SS, cavg, SS, Ke, T1 / 2, Cl / F (only fenloramide prototype), VZ / F (only fenloramide prototype), auc0-24, SS, aucinf, SS, auc0 last, SS, AUC\_ %Extrap, DF, etc. 3. Objective to explore the efficacy of fenloramide tablets in the treatment of early and mid-term Parkinson's disease, and to observe the changes of UPDRS and CGI.

Conditions

Interventions

TypeNameDescription
DRUGPhenlarmideDosage form:Tablet; Give the medicine once a day,4 weeks is a cycle of administration, a total of 3 cycles of administration.
DRUGPlaceboDosage form:Tablet; Give the medicine once a day,4 weeks is a cycle of administration, a total of 3 cycles of administration.

Timeline

Start date
2021-02-23
Primary completion
2021-10-29
Completion
2021-10-29
First posted
2021-01-05
Last updated
2022-01-03

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04693039. Inclusion in this directory is not an endorsement.